Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gestodene + ethinyl estradiol
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Femiane is a combined low-dose oral contraceptive (COC) containing the progestin gestodene (75 mcg) and the estrogen ethinyl estradiol (30 mcg). Developed by Schering AG (now Bayer), it is used primarily for the prevention of pregnancy. The mechanism of action involves the suppression of gonadotropins, which inhibits ovulation, increases cervical mucus viscosity to impede sperm penetration, and alters the endometrium to reduce the likelihood of implantation. It is typically administered in a 21-day cycle followed by a 7-day hormone-free interval. Femiane is marketed internationally and is often prescribed for women who experience side effects like weight gain or breakthrough bleeding on other progestogens.
- Brand names
- FemianeMinuletHarmonetMonevaGynera
- Other names
- gestodene + ethinyl estradiol
02
Targets
ER (Estrogen receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on gestodene + ethinyl estradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gestodene + ethinyl estradiol.